NEO, US64049M2098

NeoGenomics stock gained 3.88 percent after Q2 earnings beat

Published on 10/04/2026 at 15:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NeoGenomics stock follows a Q2 revenue beat reported July 28, with USD 201.66 million in sales. Full-year revenue guidance rose to USD 802 million-USD 806 million.

NEO, US64049M2098, Illustration mit AI erstellt.

NeoGenomics stock (ISIN US64049M2098) closed at USD 18.47 on Nasdaq on October 2, 2026, up 3.88 percent from USD 17.78. The move followed a second-quarter earnings beat and leaves the stock 7.88 percent below its 52-week high of USD 20.05.

Q2 revenue reached USD 201.66 million

NeoGenomics reported Q2 2026 revenue of USD 201.66 million, up 11.2 percent from the same quarter a year earlier, according to MarketBeat in a September 30, 2026 report. Adjusted EPS was USD 0.05 against consensus of USD 0.03, giving the quarter a USD 0.02 earnings-per-share beat.

The result was supported by clinical revenue growth of 14 percent and NGS revenue growth of 26 percent in Q2 2026. Non-clinical revenue declined 15 percent to USD 14.5 million, creating a clear split between the company's clinical expansion and its weaker research-services activity.

Guidance moved higher for 2026

NeoGenomics raised full-year 2026 revenue guidance to USD 802 million-USD 806 million from USD 797 million-USD 803 million. Adjusted EBITDA guidance also increased to USD 56 million-USD 58 million from USD 55 million-USD 57 million, according to the company's Q2 earnings discussion summarized by Investing.com on September 17, 2026.

Management lifted its NGS growth outlook to the mid-20s from the low-20s. For investors, the key operating question is whether the 26 percent Q2 NGS growth rate can offset the 15 percent decline in non-clinical revenue through the rest of 2026.

Analysts remain divided near USD 18.47

Zacks Research downgraded NeoGenomics from strong buy to hold on September 30, 2026, while six analysts held Buy ratings, three held Hold ratings and one held a Sell rating. MarketBeat listed the consensus as Moderate Buy with an average price target of USD 17.67, 4.33 percent below the October 2 closing price.

Needham raised its price target from USD 15.00 to USD 19.00 on July 29, 2026, while maintaining a Buy rating, as reported by MarketBeat. That target is 2.87 percent above the October 2 closing price, showing how the stock's recent advance has narrowed the gap to published analyst expectations.

Stock gained 3.88 percent on October 2

NeoGenomics stock closed at USD 18.47 on Nasdaq on October 2, 2026, with volume of 2,302,420 shares. Its 52-week range was USD 7.07-USD 20.05, and market capitalization stood at USD 2.4 billion.